• WP1066 Workflow for JAK2/STAT3 Research

  2026-08-08

  WP1066 is a cell-permeable JAK2/STAT3 inhibitor for connecting pathway phosphorylation events with cancer-cell phenotypes and immune-regenerative mechanisms. This workflow covers dose selection, phospho-protein validation, renal carcinoma and AML applications, and a cautious extension into macrophage-centered bone-repair research.

• EdU Imaging Kits (HF594) for PNI Research

  2026-08-07

  EdU Imaging Kits (HF594) turn S-phase DNA synthesis into a quantitative fluorescence readout for pancreatic cancer, Schwann-cell, and drug-response experiments. Their antibody-free click-chemistry workflow supports microscopy and flow cytometry while avoiding the DNA-denaturation step required by conventional BrdU assays.

• Protease Inhibitor Cocktail: Enhancing Protein Stability in

  2026-08-07

  The Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) by APExBIO is engineered for uncompromised protein integrity during cell and tissue extraction, especially in high-demand OXPHOS and signaling workflows. Its broad-spectrum, EDTA-free formulation offers seamless compatibility with kinase and metalloprotein assays where chelator interference must be avoided.

• ALDOB K87 Lactylation Orchestrates Mitochondrial Fission in

  2026-08-06

  Yi et al. identify ALDOB K87 lactylation as a central regulator of mitochondrial fission and metabolic reprogramming in pulmonary hypertension by connecting lactate-driven post-translational modification to enhanced smooth muscle cell proliferation. This mechanistic insight offers new avenues for targeting vascular remodeling in PH, with clear implications for cellular assay design and translational research.

• Triiodothyronine (T3): Mechanistic Insights and Assay Precis

  2026-08-06

  Explore the mechanistic role of Triiodothyronine (T3) in thyroid hormone receptor activation and advanced signaling assays. This article delivers a unique perspective on T3’s use in high-fidelity cellular models, bridging molecular detail and practical assay choices.

• BV6 IAP Antagonist: Precision Tools for Translational Apopto

  2026-08-05

  This thought-leadership article explores the strategic integration of BV6, a selective IAP antagonist, into translational research pipelines. Bridging mechanistic insights with actionable guidance, we highlight how BV6 advances the study of apoptosis and radiosensitization in cancer and endometriosis models, referencing both recent mechanistic studies and scenario-driven workflow solutions. The discussion expands beyond routine product summaries to address reproducibility, cross-indication applicability, and future directions in apoptosis research.

• Machine Learning Accelerates LNP Design for mRNA Vaccines

  2026-08-05

  This study introduces a machine learning-based prediction model for optimizing ionizable lipid nanoparticle (LNP) formulations in mRNA vaccine development. By integrating computational screening with molecular modeling and experimental validation, the work streamlines identification of effective lipid structures such as SM-102, offering a data-driven route to more efficient mRNA delivery systems.

• Deferasirox (Exjade): Oral Chelation Advances for Iron Overl

  2026-08-04

  The reference study establishes Deferasirox (Exjade) as the first oral tridentate chelator approved for transfusional iron overload, providing a clinically validated alternative to parenteral deferoxamine. Its efficacy, tolerability, and oral administration address major barriers in chronic anemia management, with significant implications for patient adherence and long-term outcomes.

• Foretinib (GSK1363089): Multikinase Inhibitor for Tumor Rese

  2026-08-04

  Foretinib (GSK1363089) is a potent ATP-competitive multikinase inhibitor that targets VEGFRs and MET/HGFR, showing sub-nanomolar inhibition of key kinases involved in cancer progression. It induces G2/M arrest, inhibits cell motility, and reduces tumor growth and metastasis in preclinical models, making it a valuable tool for translational cancer research.

• DiscoveryProbe™ FDA-approved Drug Library: GPCR Targeting In

  2026-08-03

  Discover how the DiscoveryProbe FDA-approved Drug Library enables innovative GPCR ligand discovery and pharmacological target identification. This article uniquely explores the intersection of structure-based screening and drug repositioning, offering fresh insights for translational research.

• Phalloidin (B7678): Technical Guidance for Actin Cytoskeleto

  2026-08-03

  Phalloidin (SKU B7678) is a cyclic heptapeptide toxin used for high-affinity stabilization and visualization of filamentous actin (F-actin) in fixed or permeabilized samples. It is optimal for static cytoskeleton analysis and microscopy-based workflows but is not suitable for live-cell imaging or studies requiring reversible actin interactions.

• Phebestin: A Potent Aminopeptidase Inhibitor Against Malaria

  2026-08-02

  The reference study identifies phebestin, a bestatin-related aminopeptidase inhibitor, as a highly effective compound with nanomolar inhibitory activity against both chloroquine-sensitive and -resistant Plasmodium falciparum strains. These findings highlight phebestin’s potential in overcoming malaria drug resistance and inform future antimalarial drug development strategies.

• Deferiprone in Iron Stress Research: Protocols and Solutions

  2026-08-01

  Deferiprone (3-hydroxy-1,2-dimethylpyridin-4-one) is transforming iron stress research by enabling precise modulation of cellular iron and dissecting iron-dependent metabolic pathways. This article unpacks stepwise workflows, troubleshooting insight, and advanced applications in cancer and enterocyte models—anchored by the latest metabolomic evidence.

• Cl-Amidine (trifluoroacetate salt): Reliable PAD4 Inhibition

  2026-07-31

  This article provides scenario-driven guidance for leveraging Cl-Amidine (trifluoroacetate salt) (SKU C3829) in cell viability, proliferation, and cytotoxicity workflows. It addresses common experimental pain points and demonstrates how this selective PAD4 inhibitor from APExBIO delivers reproducible, data-backed performance in both in vitro and in vivo research.

• iPSC-Based Clinical Trial Selection for Ultrarare Disease Th

  2026-07-31

  This study introduces a patient-specific iPSC platform to prescreen drug efficacy for ultrarare, previously uncharacterized mutations in Leigh-like syndrome. The approach allows for tailored evaluation of therapeutic candidates, potentially improving patient outcomes and refining trial selection in rare metabolic disorders.

457 records 9/31 page Previous Next First page 上5页 678910 下5页 Last page